YY1 affects the levels and function of fibulin‑5 in ox‑LDL‑treated vascular smooth muscle cells
- Leijing Wang
- Cuiyan Li
- Chunli Feng
- Yuanbo Zang
Affiliations: Department of Clinical Laboratory, Laixi Municipal Hospital, Laixi, Shandong 266600, P.R. China
- Published online on: April 21, 2022 https://doi.org/10.3892/etm.2022.11334
Copyright: © Wang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Fibulin‑5 is reportedly involved in the pathological process of atherosclerosis (AS) where low expression has been frequently observed in ruptured atherosclerotic plaques. The aim of the present study was to determine the effects of fibulin‑5 on the responses of vascular smooth muscle cells (VSMC) to oxidized low‑density lipoprotein (ox‑LDL). The expression of fibulin‑5 was studied in human aortic‑VSMCs (HA‑VSMCs) treated with ox‑LDL. Fibulin‑5 was first overexpressed by the transfection of Ov‑Fibulin‑5 plasmids in HA‑VSMCs challenged with ox‑LDL to investigate its influence on cell proliferation, migration and invasion using Cell Counting Kit‑8, wound healing and Transwell assays. Yin Yang‑1 (YY1) was bioinformatically predicted to bind to the promoter sites of fibulin‑5, which was subsequently confirmed by dual‑luciferase reporter gene assay. Fibulin‑5 overexpression was able to suppress cell proliferation, invasion and migration, which was effectively reversed by YY1 silencing by the transfection of siRNA‑Fibulin‑5 plasmids which could induced fibulin‑5 silencing. YY1 binding sites in the promoter region of fibulin‑5 were identified and confirmed in vitro by chromatin immunoprecipitation assay and dual‑luciferase reporter gene assay. The present results suggested that as a modulator of fibulin‑5, YY1 alleviated ox‑LDL‑induced proliferation, invasion, migration and phenotypic transition from differentiated contractile phenotype to dedifferentiated phenotype in VSMCs. However, the mechanism underlying the YY1‑mediated regulation of fibulin‑5 expression needs to be confirmed further in vivo. Nevertheless, targeting fibulin‑5 and YY1 could be further developed for AS therapy.